key: cord-0883548-9wu3y25f
authors: Musumeci, Maria Letizia; Caruso, Giuliana; Trecarichi, Andrea Calogero; Micali, Giuseppe
title: Safety of SARS‐CoV‐2 vaccines in psoriatic patients treated with biologics: A real life experience
date: 2021-11-15
journal: Dermatol Ther
DOI: 10.1111/dth.15177
sha: af7377e38b285b8ebc3be4c2675a8e6496175ea8
doc_id: 883548
cord_uid: 9wu3y25f

Vaccination is the most effective method to prevent and control the SARS‐CoV‐2 infection and biologics are not considered a contraindication for vaccination. The burning question is that safety data are lacking since patients taking drugs affecting the immune system were excluded from clinical trials leading to vaccine approbation. Moreover, it seems that vaccination could worsen psoriasis. We conducted a survey to investigate the safety of SARS‐CoV‐2 vaccines in psoriatic patients treated with biologics. A total of 150 patients with stable plaque psoriasis treated with biologics for at least 2 months were evaluated in a 3 months period. Fifty patients (22 F/28 M; age: 33–83 years) only underwent the first and second doses of SARS‐CoV‐2 vaccines. All patients discontinued their biological agents 10 days before and 10 days after each dose of vaccine. Of these, 24 patients were treated with anti‐TNF, 14 with anti‐IL17, 7 with anti‐IL12‐23, and 5 with anti‐IL23. After the vaccines, all patients were evaluated at day 2, 7, and 14 for local and/or systemic side effects and/or adverse drug reactions to SARS‐CoV‐2 vaccines. None of the patients experienced any side effects or a psoriatic flare. Only one patient treated with infliximab biosimilar referred an exacerbation of psoriasis after vaccine. The remaining 100 patients reported that they did not get the vaccine yet. Our preliminary data confirm that SARS‐CoV‐2 mRNA vaccines are safe for patients with chronic plaque psoriasis treated with biologics and did not trigger psoriasis, although these data should be validated in a larger population. We encourage an early SARS‐CoV‐2 vaccines administration in all psoriatic patients on immunosuppressant drugs.

to investigate the safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics. A total of 150 patients with stable plaque psoriasis treated with biologics for at least 2 months were evaluated in a 3 months period. Fifty patients (22 F/28 M; age: 33-83 years) only underwent the first and second doses of SARS-CoV-2 vaccines. All patients discontinued their biological agents 10 days before and 10 days after each dose of vaccine. Of these, 24 patients were treated with anti-TNF, 14 with anti-IL17, 7 with anti-IL12-23, and 5 with anti-IL23. After the vaccines, all patients were evaluated at day 2, 7, and 14 for local and/or systemic side effects and/or adverse drug reactions to SARS-CoV-2 vaccines. None of the patients experienced any side effects or a psoriatic flare. Only one patient treated with infliximab biosimilar referred an exacerbation of psoriasis after vaccine. The remaining 100 patients reported that they did not get the vaccine yet. Our preliminary data confirm that SARS-CoV-2 mRNA vaccines are safe for patients with chronic plaque psoriasis treated with biologics and did not trigger psoriasis, although these data should be validated in a larger population. We encourage an early SARS-CoV-2 vaccines administration in all psoriatic patients on immunosuppressant drugs. Our preliminary results confirm that SARS-CoV-2 mRNA vaccines are safe for patients with chronic plaque psoriasis treated with biologics 12 and did not trigger psoriasis, conferring a sort of protection against vaccine-related psoriatic flares, 8 although these data should be validated in a larger population. 10 

The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in this manuscript.

Maria Letizia Musumeci MD, PhD, served as advisory board member and consultant, and has received fees and speaker's honoraria or has participated to clinical trials for Abbvie, Almirall, Biogen, Eli-Lilly, Janssen Cilag, Leo Pharma, Novartis.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0002-5157-3939

Board Members of SIDeMaST. SARS-CoV-2 vaccines and biological treatments: dermatological perspectives

PSO-BIO-COVID study group. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study

National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 2-advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments. Vaccines (Basel)

Board Members of SIDeMaST. Adverse cutaneous and mucous reactions from anti SARS-CoV-2 vaccines: recommendations from the Italian Society of Dermatology (SIDeMaST)

Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single center

Dermatologists Italian Network, Malagoli P. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers

Young Dermatologists Italian Network, Damiani G. COVID-19 vaccine does not trigger psoriasis flares in psoriatic patients treated with apremilast

Reply to "psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single Centre

Skin tests in the diagnosis of adverse drug reactions

Immune response to vaccination in patients with psoriasis treated with systemic therapies. Vaccines (Basel)

Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments

A psoriatic patient-based survey on the understanding of the use of vaccines while on biologics during the COVID-19 pandemic

Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience